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Background: A new prostate cancer (PCa) prognostic grading system [Gleason groups (GGs)] has been
proposed based on the contemporary Gleason scores (GSs), which has ﬁve simpliﬁed prognostic cate-
gories. The objective of this study was to evaluate the agreement between the GGs of prostate biopsy and
radical prostatectomy specimens and to identify predictive factors for upgrading GGs.
Methods: A total of 5339 cases of RP notiﬁed to the Prostate Cancer Outcomes Registry, Victoria,
Australia over 6 years (2009e2014) from 46 hospitals, were included. The upgrading was evaluated using
the new PCa prognostic grading system, the International Society of Urologic Pathology grade groups,
which has ﬁve prognostic categories. GG 1 is GS 6, GG 2 is GS 3þ 4¼7, GG 3 is GS 4 þ 3¼7, GG 4 is GS
8, and GG 5 is GS 9 and 10. Predictors of upgrading were assessed using univariate and multivariate
models.
Results: The GG of prostate biopsies and RP specimens were concordant in 54.5% of cases, while 31.1%
were upgraded and 14.3% were downgraded. Longer time interval between biopsy and RP [44e99 days:
odds ratio (OR)¼ 1.3, 95% conﬁdence interval (CI)¼ 1.1e1.6; > 99 days: OR¼ 3.0, 95% CI¼ 2.4e3.8), and
RP performed in a metropolitan hospital (biopsy in a regional hospital: OR¼ 2.2, 95% CI¼ 1.6e3.2, biopsy
in a metropolitan hospital: OR¼ 1.7, 95% CI¼ 1.2e2.2) were signiﬁcant predictors of GG upgrading.
Patients who were diagnosed by transperineal biopsy compared to transrectal ultrasound (OR¼ 0.6, 95%
CI¼ 0.5e0.8) and higher percentage of positive biopsy cassettes (25e62.5%: OR¼ 0.7, 95% CI¼ 0.6e0.8, >
62.5: OR¼ 0.6, 95% CI¼ 0.5e0.8) were signiﬁcantly associated with less likelihood of upgrade.
Conclusion: The lack of concordance among hospitals may be attributable to the specialist expertise of
the pathologist. Expert review of specimens may help to overcome this discordance. Clinicians should
consider clinical parameters and potential limitations of the GG at biopsy when making treatment
decisions with regard to PCa.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Histopathological assessment of biopsy tissue is the mainstay of
diagnosing prostate cancer (PCa).1 The Gleason score (GS) of biopsy
material is a key parameter and plays a vital role in diagnosticrtment of Epidemiology and
rcial Road, Melbourne 3004,
s).
ciﬁc Prostate Society, Published bevaluation, risk stratiﬁcation, prognostication, and management
decisions regarding PCa.2
GS upgrading refers to ﬁnding a higher grade in the operative
specimen at radical prostatectomy (RP) thanwas seen in the biopsy,
and is associated with poorer outcomes.3 Studies have demon-
strated signiﬁcant histopathological discordance rates up to 62.8%,4
with inaccurate biopsy specimensmore typically undergraded than
overgraded when compared with RP.
Many studies have examined variables that may help to predict
pathological upgrading of GS from biopsy to RP, including highy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 145e151146prostate-speciﬁc antigen (PSA) level,5 advanced patient age,5 the
level of pathologist expertise,6 time from biopsy to surgery,7 serum
testosterone level,8 treatment with brachytherapy,9 percentage
tumor involvement,10 prostate size or volume,1 and number of core
biopsies.11
A new PCa prognostic grading system has been proposed based
on the contemporary GS, which is known as Gleason groups (GGs).
It has ﬁve simpliﬁed prognostic categories that use a scale of 1e5.12
The new PCa grading system is more accurate in grade stratiﬁcation
than previous systems, and the lowest grade is 1, as compared to 6
in the previous system, with the potential to reduce overtreatment
of PCa.13 There are limited data evaluating this new proposed GG
system. One study has been conducted to investigate pathological
outcomes using the new GGs,14 another to verify whether the new
GGs yield signiﬁcant prognostic differences,13 and one to examine
the performance of the new GGs in men with PCa from a nation-
wide population-based cohort.15
In this study, we evaluated the agreement between the GGs of
prostate biopsy and RP specimens and identify predictive factors
for upgrading the GG in a cohort of men in Victoria, Australia.
2. Materials and methods
2.1. Study population
The Prostate Cancer Outcomes Registry, Victoria (PCOR-Vic,
previously known as the Victorian Prostate Cancer Registry; VCR) is
a rapid case-ascertainment population-based registry established
in 2009 as a means of investigating variation in cancer presentation
and care provided to PCa patients in Victoria. Methods for partici-
pant recruitment and data collection have previously been
described.16 Men with biopsy-conﬁrmed PCa diagnosis, in partici-
pating Victorian hospitals were notiﬁed to the PCOR-Vic. Clinical
data were collected by trained data collectors through medical re-
cords, and histopathological data were captured through hospital
information systems and pathology reports and de-identiﬁed. The
biopsy and RP specimens were performed at a large number of
institutions throughout Victoria, including teaching hospitals and
private pathology laboratories. Given the wide range of institutions
involved, no standardized handling of the surgical specimens was
possible, and the specimens were reported by numerous patholo-
gists with no central review.
2.2. Statistical analysis
For our analysis, biopsy GS and RP GS were classiﬁed into GGs as
described above. GS 6 was GG 1, GS 3þ 4¼7 was GG 2, GS 4 þ
3¼7 was GG 3, GS 8 was GG 4, and GS 9 and 10 was GG 5. The
grades of the prostate biopsy and RP specimens were considered to
be concordant if the GG was the same for the highest grade tumor
in the prostate biopsy and the index tumor in the RP. Upgrading
was deﬁned as an increase in the GG of the RP specimens compared
to the prostate biopsy GG. Cases with GS 10 at diagnosis were
excluded, as that category cannot be upgraded, before dividing the
patients into concordant and upgrade groups.
Patients' age at diagnosis, preoperative serum PSA level, number
of biopsy cassettes, number of positive biopsy cassettes, the time
interval between initial biopsy and RP, and RP annual surgeon
volume were analyzed as continuous variables. The year of diag-
nosis, method of diagnosis, clinical categories (cT1, cT2, and cT3/4),
percentage of positive biopsy cassettes (< 25%, 25e62.5%, and >
62.5% based on quartiles where percentage of cores positive was
operationally deﬁned as the percentage of individually labeled
pathological specimens containing PCa of any amount, divided by
the total number of individually labeled specimens received),National Comprehensive Cancer Network classiﬁcation, RP ap-
proaches (robot-assisted laparoscopic RP, laparoscopic RP, or open
retropubic RP) and the hospitals where the biopsy/RP was per-
formed (private vs. public and metropolitan vs. regional), patho-
logical categories (pT2/pT3/pT4), positive surgical margin status,
and extraprostatic extensionwere analyzed as categorical variables.
The annual surgeon volume was calculated by dividing the total
number of RP procedures performed by each surgeon over the
number of years they have contributed data to the PCOR-Vic. As the
PCOR-Vic collects data on ~75% of men diagnosed with PCa, the
surgeon volume calculate by PCOR-Vic was compared with that
collected by the VCR, which collects surgeon details on all RPs in
Victoria. There was no signiﬁcant difference in annual surgeon
volume between PCOR-Vic and VCR.
The differences in these factors in patients with concordant
versus upgraded GG were compared using the ManneWhitney U
test for continuous variables and Pearson's c2 test for categorical
variables. The effect of each of these factors on the odds of GG
upgrading was analyzed using the univariate ordered logistic
regression model, with odds ratios (ORs) and their corresponding
95% conﬁdence intervals (CIs) provided as measures of effect size.
Factors that were signiﬁcant in the univariate analyses were
included in the multivariate logistic regression model using the
stepwise method. All statistical analyses were performed using
STATA version 13 (StataCorp LP, College Station, TX, USA) and the
level of signiﬁcance was set at 5%.
2.3. Ethical approval
The study was approved by the Health Research Ethics Com-
mittee of each participating hospital as well as the Monash Uni-
versity Health Research Ethics Committee (Melbourne, Victoria,
Australia; CF09/0931 e 2009000436) and the Cancer Council Vic-
toria (Project No. 0908).
3. Results
Between January 2009 and December 2014, 12,366 PCa patients
were included in the PCOR-Vic. Of these, 5,693 patients proceeded
to have RP as their primary treatment. Three hundred and sixteen
patients were excluded because the GS was missing for the biopsy,
RP, or both the biopsy and RP. A further 38 patients who received
radiotherapy (3) or androgen therapy (35) prior to RP were
excluded as these treatments may affect the histopathology of the
RP specimens. A total of 5,339 patients with complete information
on paired biopsy and RP specimen histopathology were included in
the current study.
Table 1 shows the clinical and demographic information of the
patients in the study. The median age at diagnosis was 63.0 years
[interquartile range (IQR)¼ 57.7e67.0]. Most patients (91.3%) were
diagnosed via transrectal ultrasound (TRUS)-guided biopsy. RP was
performed at a median of 59 days (IQR¼ 40e99) after diagnosis
and 2,821 (52.8%) patients had robot-assisted laparoscopic RP,
while 2,156 (40.4%) had open retropubic RP. The majority of the
patients (72.2%) had the biopsy and RP performed in a private
hospital. The median annual surgeon volumewas 33 (IQR¼ 19e53)
and most patients were histologically categorized into pT2 or pT3
categories (93.2%).
Table 2 shows the GG of the RP specimens stratiﬁed by biopsy
GG. For the GG reported for the RP specimens, 2,911 (54.5%) were
unchanged compared to the GG of the diagnostic biopsy (i.e.,
concordant), while 1,662 (31.1%) of the RP GGs were upgraded and
766 (14.3%) were downgraded (Table 3). In reviewing each grade
group, the most frequent upgrading occurred in men with GG 1 on
biopsy, who were upgraded in 69.7% of cases, mainly into GG 2,
Table 1
Preoperative and postoperative clinicopathological characteristics of the study
population (N¼ 5,339).
Characteristic n (%)
Age at diagnosis (y)
Median (IQR) 63 (57.7e67)
Y of diagnosis (biopsy)
2009 467 (8.7)
2010 567 (10.6)
2011 1162 (21.7)
2012 1186 (22.2)
2013 1060 (19.8)
2014 897 (16.8)
Method of diagnosis
TRUS 4876 (91.3)
TURP 93 (1.7)
Transperineal biopsy 359 (6.7)
Other (TURBT, prostatectomy) 9 (0.2)
Not stated 2 (0.04)
Preoperative serum PSA level (ng/mL)
Median (IQR) 6 (4.5e8.3)
Clinical categories
cT1 2,407 (45.1)
cT2 1,606 (30.1)
cT3/cT4 217 (4.0)
Not stated 1,109 (20.7)
No. of biopsy cassettes
Median (IQR) 8 (6e8)
No. of positive biopsy cassettes
Median (IQR) 3 (2e5)
Positive biopsy cassettes (%)
Median (IQR) 42.8 (25e62.5)
< 25 1025 (19.2)
25e62.5 2882 (53.9)
> 62.5 1273 (23.8)
Not stated 159 (2.9)
NCCN Classiﬁcation
Low risk 909 (17.0)
Intermediate risk 3007 (56.3)
Metastatic risk 1,134 (21.2)
Not stated 289 (5.4)
Interval between biopsy & surgery (d)
Median (IQR) 59 (40e99)
< 40 1,327 (24.8)
40e99 2,675 (50.1)
> 99 1,330 (24.9)
Not stated 7 (0.1)
RP approach
Robot-assisted laparoscopic 2,821 (52.8)
Laparoscopic 317 (5.9)
Open retropubic 2,156 (40.4)
Not stated 45 (0.8)
Hospital where biopsy/RP performed
Private/private 3,853 (72.2)
Private/public 207 (3.8)
Public/private 189 (3.5)
Public/public 793 (14.8)
Not stated 297 (5.5)
Hospital where biopsy/RP performed
Metropolitan/metropolitan 4,153 (77.8)
Metropolitan/regional 13 (0.2)
Regional/metropolitan 500 (9.3)
Regional/regional 454 (8.5)
Not stated 219 (4.1)
RP annual surgeon volume
Median (IQR) 33 (19e53)
Pathological categories
pT2 2,901 (54.3)
pT3 2,078 (38.9)
pT4 8 (0.1)
Not stated 352 (6.6)
Positive surgical margin
Absent 3,798 (71.1)
Present 1,449 (27.1)
Not stated 92 (1.7)
Table 1 (continued )
Characteristic n (%)
Extraprostatic extension
No 874 (16.3)
Yes 924 (17.3)
Data collected prior to database 3,296 (61.7)
Not stated 245 (4.1)
IQR, interquartile range; NCCN, National Comprehensive Cancer Network; PSA,
prostate-speciﬁc antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound;
TURBT, transurethral resection of a bladder tumor; TURP, transurethral resection of
the prostate.
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Downgrading was more commonly seen in men with GG 3 and GG
4 on biopsy, with downgrading in 29.7% and 60.1%, respectively, in
these two groups. Of the ﬁve grade groups, GG 1 and GG 4 were the
least predictive of the ﬁnal grade at RP.
Table 4 shows the characteristics of patients who have concor-
dant and upgraded GG. Age at diagnosis, year of diagnosis, method
of diagnosis, clinical categories at diagnosis, number and percent-
age of positive biopsy cassettes, time interval between biopsy and
surgery, place where biopsy and surgery were performed, median
annual surgeon volume, and status of positive surgical marginwere
signiﬁcantly associated with GG upgrading.
Results of univariate and multivariate analysis are shown in
Table 5. Higher age at diagnosis was associated with reduced risk of
GG upgrading (OR¼ 0.98, 95% CI¼ 0.97e0.99). Men diagnosed in
more recent years were less likely to be upgraded (2013: OR¼ 0.7,
95% CI¼ 0.6e0.9; 2014: OR¼ 0.5, 95% CI¼ 0.4e0.7) than those
diagnosed in 2009. Patients who were diagnosed by transperineal
biopsy were less likely to be upgraded (OR¼ 0.6, 95% CI¼ 0.5e0.8).
When compared with the total number of cassettes used in the two
methods of diagnosis, the median number of cassettes in TRUS was
7.9 and the mean number of cassettes used in transperineal biopsy
was 9.7. This difference between the mean values was signiﬁcant (2
sample Wilcoxon rank sum test¼2.2, P¼ 0.02). Men with a
clinical T category of cT3/4 were less likely than those diagnosed
with cT1 to have GG upgrading (OR¼ 0.6, 95% CI¼ 0.4e0.8). A
higher number of positive biopsy cassettes (OR¼ 0.9, 95%
CI¼ 0.8e0.9) and higher percentage of positive biopsy cassettes
was associatedwith reduced likelihood of GG upgrading. Compared
with those with < 25% positive cassettes, 25e62.5% positive cas-
settes had OR of 0.6 (95% CI¼ 0.5e0.7), and > 62.5% positive cas-
settes had OR of 0.5 (95% CI¼ 0.4e0.6). A longer interval between
diagnosis and RP was associated with increased risk of GG
upgrading. Compared with < 40 days, 40e99 days had a 1.4 times
higher risk of upgrade (OR¼ 1.4, 95% CI¼ 1.1e1.6), and > 99 days
had a three times higher risk of upgrade (OR¼ 3.1, 95%
CI¼ 2.6e3.7). Additionally, patients who had both biopsy and RP
performed in private hospitals were less likely to have GG
upgrading, compared with those who had biopsy and surgery in
public hospitals (OR¼ 0.6, 95% CI¼ 0.5e0.8). Lastly, patients who
had RP in a metropolitan hospital irrespective of the place of biopsy
were more likely to have GG upgrading (biopsy at a regional hos-
pital: OR¼ 2.3, 95% CI¼ 1.7e3.1, biopsy at a metropolitan hospital:
OR¼ 1.2, 95% CI¼ 1.0e1.6).
Inmultivariate analysis, a longer interval between biopsy and RP
(44e99 days: OR¼ 1.3, 95% CI¼ 1.1e1.6; > 99 days: OR¼ 3.0, 95%
CI¼ 2.4e3.8), and RP performed in a metropolitan hospital (biopsy
in a regional hospital: OR¼ 2.2, 95% CI¼ 1.6e3.2; biopsy in a
metropolitan hospital: OR¼ 1.7, 95% CI¼ 1.2e2.2) remained as
signiﬁcant predictors of GG upgrading. Patients who were
Table 2
Gleason groups of biopsy and RP specimens.
Biopsy Gleason groups RP specimens Gleason groups, n (%)
1 ( 6) 2 (3þ 4) 3 (4þ 3) 4 (8) 5 (9 & 10) Total
1 ( 6) 438 (30.3) 787 (54.5) 175 (12.1) 15 (1.0) 31 (2.1) 1,446 (100.0)
2 (3þ 4) 71 (3.4) 1545 (74.7) 382 (18.6) 32 (1.5) 38 (1.8) 2,068 (100.0)
3 (4þ 3) 19 (2.1) 255 (27.6) 551 (59.7) 35 (3.8) 63 (6.8) 923 (100.0)
4 (8) 4 (0.7) 83 (16.0) 229 (44.0) 100 (19.2) 104 (20.1) 520 (100.0)
5 (9 & 10) 3 (0.8) 18 (4.7) 63 (16.5) 21 (5.5) 277 (72.5) 382 (100.0)
Total 535 (10.0) 2,688 (50.3) 1400 (26.2) 203 (3.8) 513 (9.7) 5,339 (100.0)
RP, radical prostatectomy.
Table 3
Prostate biopsy and RP specimen GG concordance rate.
RP specimen GG, n (x, y%)
Biopsy GG Downgraded n (x, y) Concordant n (x, y) Upgraded by any group n (x, y) Total n (x, y) Upgraded by 1 group n (x) Upgraded by  2 groups n (x)
1 ( 6) 0 (0.0, 0.0) 438 (15.0, 30.3) 1008 (60.6, 69.7) 1,446 (27.0, 100.0) 787 (60.2) 221 (62.4)
2 (3þ 4) 71 (9.3, 3.4) 1545 (53.1, 74.7) 452 (27.2, 21.8) 2,068 (38.7, 100.0) 382 (29.2) 70 (19.8)
3 (4þ 3) 274 (35.8, 29.7) 551 (18.9, 59.7) 98 (5.9, 10.6) 923 (17.3, 100.0) 35 (2.7) 63 (17.8)
4 (8) 316 (41.2, 60.8) 100 (3.4, 19.2) 104 (6.3, 20.0) 520 (9.7, 100.0) 104 (7.9) 0
5 (9 & 10) 105 (13.7, 27.5) 277 (9.5, 72.5) 0 (0.0, 0.00) 382 (7.1, 100.0) 0 0
Total 766 (100.0, 14.3) 2911 (100.0, 54.5) 1662 (100.0, 31.1) 5339 (100.0, 100.0) 1308 (100.0) 354 (100.0)
GG, Gleason group; RP, radical prostatectomy.
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95% CI¼ 0.5e0.8) and higher percentage of positive biopsy cas-
settes (25e62.5%: OR¼ 0.7, 95% CI¼ 0.6e0.8; > 62.5%: OR¼ 0.6,
95% CI¼ 0.5e0.8) remained as signiﬁcant factors for less likelihood
of upgrade. Age at diagnosis, year of diagnosis, clinical T categories,
and number of positive biopsy cassettes were no longer signiﬁ-
cantly associated with upgrading.
4. Discussion
This study demonstrates that despite efforts of standardization,
inaccuracy of PCa biopsy persists in Victoria with discrepancies in
GG between biopsy and RP. This has signiﬁcant clinical implications
for management of PCa; both on an individual and public health
level. Concordance between biopsy and RP specimens was seen
54.5% of the time, and if not concordant, GG was more likely to be
upgraded. In our cohort, lower GG (GG 1) on biopsy wasmore likely
to be upgraded on RP (60.6%). After multivariate analysis, the pre-
dictors of GG upgrading were the time interval between biopsy and
RP, the hospital where the RP was performed, method of diagnosis,
and percentage of positive biopsy cassettes.
An Australian population-based series of RP undertaken between
1995 and 2000 demonstrated low concordance between prostate
biopsy and RP (31%), with 42% of biopsy specimens undergraded.17
The difference between their average level of concordance and
ours (31% vs. 54%) may reﬂect an improvement of accuracy in
Australia over time. However, lack of uniformity in the various
grading systems, especially the allocation of histology to grades
changed after International Society of Urologic Pathology 2005,18
and that precludes meaningful comparison between studies.
There are several possible explanations for upgrading of PCa.
First, it may reﬂect interobserver variation among the pathologists.
A means of overcoming discrepancy between biopsy and RP GGs
would be to have biopsy specimens examined by higher-volume,
centrally located pathologists prior to making treatment de-
cisions. Indeed, it has been suggested that a second opinion on
prostate biopsy specimens should be mandatory as expert review
may lead to a signiﬁcant difference in score and hence recom-
mended therapy.19 Second, upgrading may reﬂect sampling error,
where a small sample of PCa obtained on biopsy may not be
representative of the cancer as a whole. As such, the grade onbiopsy frequently differs from the ﬁnal GG of the RP specimen;
potentially with signiﬁcant clinical repercussions.20 It follows that
the amount of tumor in the biopsy should be considered when
gauging the likely true pathology. In our study, having > 25% of the
biopsy specimens positive for cancer was associated with a higher
level of concordance between biopsy and RP GG, compared with
having < 25% of the specimens positive for cancer. While per-
centage of positive biopsy cores is a proxy measure of tumor vol-
ume, limited literature on the correlation between percentage
tumor volume and accuracy of tumor grade exists. Our results are
consistent with previous studies that demonstrated an inverse
relationship between percentage of positive cores and GG
upgrading.6 The literature suggests this sampling error can be
overcome in part by taking more cores, with reports that increased
number of cores taken at the time of biopsy achieve improved
concordance.21 This improvement in sampling is possible with
transperineal biopsies, and although limited, the data presented
here show better concordance of tumor grade between biopsy and
RP for transperineal biopsy than TRUS biopsy.
Several studies have investigated predictors of upgrading in the
literature with conﬂicting results; our aim was to strengthen the
evidence base. Predictors from the literature include low prostate
volume/weight,3 higher PSA level,5,22,23 higher PSA density,24 older
age,5 clinical stage T2,25 time interval between diagnosis to RP,7,23
percentage positive biopsy cores,7,22 Cancer of the Prostate Risk
Assessment (CAPRA) score,22 higher body mass index,22,24 and low
serum testosterone.8
Our results demonstrate that a longer interval between diag-
nostic biopsy and surgery is predictive of upgrading. This is
consistent with previous ﬁndings.7,23 Furthermore, we have shown
that a delay of > 9 months or even 6 months not only predicted
upgrading, but was also associated with greater biochemical
recurrence and positive surgical margins,26 suggesting that a delay
may compromise patient outcomes. An alternative explanation
would be that the association is confounded by subsequent biopsies
after the initial biopsy, which showed more advanced disease, in
turn prompting RP.
We found that the method of diagnostic biopsy is a predictor for
Gleason upgrading. Patients diagnosed using transperineal biopsy,
introduced recently into clinical practice in Victoria, were less likely
to be upgraded compared to those undergoing TRUS biopsies.
Table 4
Characteristics of patients with concordant versus upgraded Gleason groups
Characteristic Concordant (a)n¼ 2,891) Upgraded (n¼ 1,662) Pb)
Age at diagnosis (y) 62.1 61.5 0.003
Year of diagnosis (biopsy)
2009 239 (8.3) 164 (9.8) < 0.001
2010 268 (9.3) 194 (11.7)
2011 601 (20.8) 364 (21.9)
2012 633 (21.9) 397 (23.9)
2013 603 (20.8) 318 (19.1)
2014 547 (18.9) 225 (13.5)
Diagnostic method
TRUS 2620 (90.9) 1535 (92.4) 0.004
TURP 46 (1.6) 39 (2.3)
Transperineal biopsy 215 (7.5) 87 (5.2)
Preoperative PSA level (ng/mL) 7.6 7.4 0.5
Clinical categories,
cT1 1280 (56.6) 814 (60.4) 0.01
cT2 857 (37.9) 485 (35.9)
cT3/4 125 (5.5) 49 (3.6)
No. of biopsy cassettes 8.01 8.02 0.8
No. of positive biopsy cassettes 3.5 3.2 < 0.001
Positive biopsy cassettes (%)
< 25 502 (17.9) 419 (26.1) < 0.001
25e64.2 1,592 (56.8) 870 (54.1)
> 64.2 709 (25.3) 318 (19.8)
Interval between biopsy & surgery (d)
< 40 796 (27.5) 280 (16.8) < 0.001
40e99 1,509 (52.3) 744 (44.8)
> 99 582 (20.2) 638 (38.4)
Surgical approach
robot-assisted laparoscopic RP 1,538 (53.8) 916 (55.3) 0.2
Laparoscopic prostatectomy 191 (6.7) 91 (5.5)
Open prostatectomy 1,127 (39.5) 650 (39.2)
Hospital where RP performed
Private/private 2192 (79.8) 1119 (72.3) < 0.001
Private/public 105 (3.8) 70 (4.5)
Public/private 80 (2.9) 82 (5.3)
Public/public 368 (13.4) 276 (17.8)
Hospital where biopsy/RP performed
Metropolitan/Metropolitan 2,293 (82.3) 1244 (78.8) < 0.001
Metropolitan/regional 6 (0.2) 6 (0.3)
Regional/metropolitan 214 (7.7) 213 (13.5)
Regional/regional 272 (9.8) 115 (7.3)
RP median annual surgeon volume 34.5 36.7 0.0009
Pathological T categories
pT2 1,598 (59.4) 904 (57.8) 0.3
pT3 1,092 (40.6) 659 (42.2)
Positive surgical margin
Absent 2,108 (74.2) 1,136 (69.3) < 0.001
Present 732 (25.7) 502 (30.6)
Extraprostatic extension
No 493 (49.5) 280 (48.6) 0.7
Yes 503 (50.5) 296 (51.4)
Data are presented as n (%).
For continuous variables, median, and for categorical variables, n (%) is shown.
a) Patients who had Gleason sum score at diagnosis ¼10 were excluded in the analysis.
b) Numerical-ManneWhitney U test, categorical e chi square test/ﬁshers exact depending on the number in each cell.
PSA, prostate-speciﬁc antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound; TURP, transurethral resection of the prostate.
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transperineal biopsy method, hence this should be interpreted
carefully. Few studies have demonstrated this association. In one
recent study,27 the likelihood of upgrade with transperineal bi-
opsies (30.41%) was less than with TRUS biopsies (33.22%), but the
reduction was not statistically signiﬁcant (P¼ 0.55).
The factor most signiﬁcantly associated with upgrading related
to where biopsies and surgery was undertaken. GG upgrading was
signiﬁcantly more likely to occur if the surgery was carried out in a
metropolitan hospital compared with a regional hospital, irre-
spective of the place of biopsy. Although there is variability in the
level and type of services available in regional areas compared to
metropolitan (urban and more developed) areas,28 the reasons forthis are uncertain and require further investigation. It may reﬂect
that the skill of the pathologist affected the agreement between the
two sets of pathologists. This interobserver variationwas conﬁrmed
in a previous study inwhich all biopsies were reviewed by a central
panel and a consensus opinion was achieved. It demonstrated that
there was a high degree of concordance between the original GS
and the consensus scores derived from the central review (28%).29
Our data did not support the predictive power of preoperative
PSA level in GG upgrading. Variable evidence exists for an associ-
ation between preoperative PSA and upgrading, with some litera-
ture in support of higher PSA levels correlating with upgrading in
some,23 while other studies show that PSA is not helpful in pre-
dicting Gleason upgrading.4
Table 5
Factors predictive of RP specimen Gleason group upgrading in univariate and multivariate logistic regressionb)
Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Age at diagnosis 0.98 0.97e0.99 0.008 e
Y of diagnosis (biopsy)
2009 Reference
2010 1.0 0.8e1.3 0.6 e
2011 0.8 0.6-1.1 0.3
2012 0.9 0.7e1.1 0.4
2013 0.7 0.6e0.9 0.03
2014 0.5 0.4e0.7 < 0.001
Diagnostic method
TRUS Reference
TURP 1.4 0.9e2.2 0.09
Transperineal biopsy 0.6 0.5e0.8 0.005 0.6 0.5e0.8 < 0.001
Preoperative serum PSA level (ng/mL) 0.9 0.9e1.0 0.5 a) e e
Clinical categories at diagnosis
cT1 Reference e e e
cT2 0.8 0.7e1.0 0.1
cT3/4 0.6 0.4e0.8 0.006
No. of biopsy cassettes 1.0 0.9e1.0 0.8 a) e e
No. of positive biopsy cassettes 0.9 0.8e0.9 < 0.001
Positive biopsy cassettes (%)
< 25 Reference Reference
25e62.5 0.6 0.5e0.7 < 0.001 0.7 0.6e0.8 0.002
> 62.5 0.5 0.4e0.6 < 0.001 0.6 0.5e0.8 < 0.001
Interval between biopsy & surgery (d)
< 40 Reference
40e99 1.4 1.1e1.6 < 0.001 1.3 1.1e1.6 0.002
> 99 3.1 2.6e3.7 < 0.001 3.0 2.4e3.8 < 0.001
Surgical approach
Robot-assisted LRP Reference a)
LRP 0.7 0.6e1.0 0.09 e e e
Open retropubic RP 0.9 0.8e1.0 0.6 e e e
Hospital where biopsy/RP performed
Public/public Reference Reference
Public/private 1.3 0.9e1.9 0.07 1.6 1.0e2.3 0.01
Private/public 0.8 0.6e1.2 0.4 0.7 0.5e1.1 0.1
Private/private 0.6 0.5e0.8 < 0.001 0.9 0.7e1.1 0.3
Hospital where biopsy/RP performed
Regional/regional Reference
Regional/metropolitan 2.3 1.7e3.1 < 0.001 2.2 1.6e3.2 < 0.001
Metropolitan/regional 2.3 0.7e7.4 0.1 4.8 0.8e29.7 0.08
Metropolitan/metropolitan 1.2 1.0e1.6 0.03 1.7 1.2e2.2 < 0.001
RP median annual surgeon volume 1.005 1.002e1.008 < 0.001
Pathological T categories
pT2 Reference a)
pT3 1.0 0.9e1.2 0.3
Surgical margins
Absent Reference a)
Present 1.2 1.1e1.4 < 0.001
Extraperitoneal invasion
No Reference a)
Yes 1.03 0.8e1.2 0.7
a) Variables not entered in to the ﬁnal model.
b) Dependent variable was upgraded 0e4 in an ordered logistic model.
CI, conﬁdence interval; LRP, laparoscopic radical prostatectomy; OR, odds ratio; PSA, prostate-speciﬁc antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound;
TURP, transurethral resection of the prostate.
Prostate Int 4 (2016) 145e151150The strengths of our study were that the PCOR-Vic is a registry
that collects data systematically on PCa; the data are collected by
trained staff; and it captures a complete summary of patient his-
tory, diagnosis, treatment, and quality of life outcomes of patients
diagnosed with PCa in Victoria. Recruitment occurs from hospitals
concurrently with cancer notiﬁcations to the VCR. All Victorian
hospitals, pathology services, and prescribed registers (public or
private) are mandated to report cancer diagnosis information to the
VCR.16
There were several limitations to our study. The new GGs were
not entirely a straight transfer of GS to GG but also considered
tertiary patterns as well. However, PCOR-Vic does not collect data
about the tertiary pattern. In addition, the PCOR-Vic does notcollect details of the pathologist reviewing the specimen or how
the RP specimens are submitted, and other potential contributing
factors such as prostate volume, patient symptoms, body mass in-
dex, and other past medical or social history. As such, we cannot
determine the extent to which these variables explain the variation
or perhaps moderate our existing ﬁndings. The PCOR-Vic currently
collects data from ~75% of the Victorian population. As such, it is
difﬁcult to generalize our ﬁndings to regions not represented in the
registry.
In conclusion, much international data exists, but a large cohort
of Australian men has not been evaluated with regard to concor-
dance and predictive factors. Our data suggest the need for mea-
sures to enhance consistency of pathological assessment of prostate
Evans et al / Prostate cancer Gleason Groups 151biopsies due to the high rate of discordance and the importance of
GG as a parameter in risk stratiﬁcation and management decision-
making. Measures might include central review, or enhancing or
supporting pathological reporting in regional Victoria. It is impor-
tant for the clinician and patient to consider potential limitations of
the GG at biopsy and how well it represents the true pathology
when making treatment decisions.
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